Development of therapy approach in Patient with Chronic Granulocity Leukemia: Case Report
By:
References
- Spiers AS. Clinical manifestations of chronic granulocytic leukemia. Semin Oncol. 1995 Aug;22(4):380–95.
- Saußele S, Silver RT. Management of chronic myeloid leukemia in blast crisis. Ann Hematol. 2015 Apr;94 Suppl 2:S159–65. doi: 10.1007/s00277-015-2324-0.
- Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015 Jun;6(6):403–12. doi: 10.1007/s13238-015-0143-7.
- Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010 Oct;47(4):302–11. doi: 10.1053/j.seminhematol.2010.07.001.
https://www.cancer.gov/publications/cancerterms/def/chronic-granulocytic-leukemia - 6.
Eden RE, Coviello JM. Cancer, Leukemia, Myelogenous, Chronic (CML, Chronic Granulocytic Leukemia). 2018 Oct 27. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan- Available from
http://www.ncbi.nlm.nih.gov/books/NBK531459/ EdenRE CovielloJM Cancer, Leukemia, Myelogenous, Chronic (CML, Chronic Granulocytic Leukemia) 2018 Oct 27 StatPearls [Internet] Treasure Island (FL) StatPearls Publishing 2018 Jan- Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK531459/ - Shao X, Chen D, Xu P, Peng M, Guan C, Xie P, Yuan C, Chen B. Primary Philadelphia chromosome positive acute myeloid leukemia: A case report. Medicine (Baltimore). 2018 Nov;97(44):e12949. doi: 10.1097/MD.0000000000012949.
- Kuan JW, Su AT, Leong CF, Osato M, Sashida G. Systematic review of pre-clinical chronic myeloid leukaemia. Int J Hematol. 2018 Nov;108(5):465–484. doi: 10.1007/s12185-018-2528-x.
- Marchetti M. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Rev Pharmacoecon Outcomes Res. 2017 Oct;17(5):469–480. doi: 10.1080/14737167.2017.1366858.
- Rajpal S, Nampoothiri RV, Sreedharanunni S, Parihar M, Malhotra P, Varma N. Granulocytic dysplasia: an indicator of clonal evolution in patients with chronic myeloid leukemia. Blood Res. 2018 Jun;53(2):180–181. doi: 10.5045/br.2018.53.2.180.
- Bhatia R. Novel approaches to therapy in CML. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):115–120. doi: 10.1182/asheducation-2017.1.115.
- Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e71–e73. doi: 10.1016/j.clml.2017.09.004.
- 13.
Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clin Cancer Res. 2017 Dec 1;23(23):7180–7188. doi:
m10.1158/1078-0432.CCR-17-0957
.
KwakJY KimSH OhSJ ZangDY KimH KimJA DoYR KimHJ ParkJS ChoiCW LeeWS MunYC KongJH ChungJS Shin HJ Kim DY Park J Jung CW Bunworasate U Comia NS Jootar S Reksodiputro AH Caguioa PB Lee SE Kim DW Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Clin Cancer Res. 2017 Dec 1 23 23 7180 7188 m10.1158/1078-0432.CCR-17-0957
- Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase ½ study. Int J Hematol. 2017 Sep;106(3):385–397. doi: 10.1007/s12185-017-2238-9.
- Fischer JT, Ho AD, Wilhelm M, Goebeler ME, et al. German CML Study Group. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia. 2016 Mar;30(3):562–9. doi: 10.1038/leu.2015.281.
- Jiang Q, Zhao D, Jin J, Wu D, Meng F, Hu J, Liu B, DU X, Liu T, Li Y, Hou M, Han X, Shen Z, Ma J. [A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2015 Aug;36(8):651–5. doi: 10.3760/cma.j.issn.0253-2727.2015.08.005.
- Hochhaus A, Rosti G, Cross NC, Steegmann JL, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016 Jan;30(1):57–64. doi: 10.1038/leu.2015.270.
Language: English
Page range: 285 - 288
Submitted on: Dec 17, 2018
Accepted on: Dec 30, 2018
Published on: Feb 27, 2022
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2022 Predrag Krstic, Marija Elez, Biljana Zivanovic-Todoric, Gordana Ostojic, Bela Balint, Milomir Malesevic, Dragana Stamatovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.